Skip to main content

Enanta Pharmaceuticals Inc

ENTA
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001177648

No open-market purchases or sales by Enanta Pharmaceuticals Inc insiders were filed in the last 90 days; 122 institutions reported holding it in 13F filings for Q2 2026, worth $397.2M in total; no superinvestor holds it.

Q2 2024 vs. Q1 2024

How the institutions holding Enanta Pharmaceuticals Inc changed between Q1 2024 and Q2 2024.

All holders in Q2 2024All holders in Q1 2024

13F holders of ENTA: Q1 2024 compared with Q2 2024
MeasureQ1 2024Q2 2024Change
Holders108101−7
Shares22.4M22.1M−278.6K (−1.2%)
Value$391.4M$287.0M−$104.4M (−26.7%)

New holders (11)

Institutions that held Enanta Pharmaceuticals Inc at the end of Q2 2024 but not at the end of Q1 2024.

Institutions new to ENTA in Q2 2024
InstitutionSharesValue% of portfolio
Y-Intercept (Hong Kong) Ltd45,999$596.6K0.03%
Norges Bank40,700$527.9K0.00%
Walleye Capital LLC22,349$289.9K0.00%
Jump Financial, LLC15,200$197.1K0.00%
Corebridge Financial, Inc.10,807$140.2K0.00%
Mirae Asset Global ETFs Holdings Ltd.9,762$126.6K0.00%
Allspring Global Investments Holdings, LLC2,667$34.6K0.00%
SRS Capital Advisors, Inc.128$1.66K0.00%
Picton Mahoney Asset Management79$1.00K0.00%
Innealta Capital, LLC16$2080.00%
Rothschild Investment LLC10$1300.00%

Sold out (18)

Institutions that held Enanta Pharmaceuticals Inc at the end of Q1 2024 and filed for Q2 2024 without it.